The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Lupin enters into BTA with Lupin Manufacturing Solutions
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Subscribe To Our Newsletter & Stay Updated
